SG11201807336RA - Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof - Google Patents
Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereofInfo
- Publication number
- SG11201807336RA SG11201807336RA SG11201807336RA SG11201807336RA SG11201807336RA SG 11201807336R A SG11201807336R A SG 11201807336RA SG 11201807336R A SG11201807336R A SG 11201807336RA SG 11201807336R A SG11201807336R A SG 11201807336RA SG 11201807336R A SG11201807336R A SG 11201807336RA
- Authority
- SG
- Singapore
- Prior art keywords
- massachusetts
- international
- antibodies
- california
- march
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662309383P | 2016-03-16 | 2016-03-16 | |
US201662309365P | 2016-03-16 | 2016-03-16 | |
US201662309374P | 2016-03-16 | 2016-03-16 | |
PCT/US2017/022188 WO2017160775A1 (en) | 2016-03-16 | 2017-03-13 | Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807336RA true SG11201807336RA (en) | 2018-09-27 |
Family
ID=59852234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807336RA SG11201807336RA (en) | 2016-03-16 | 2017-03-13 | Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20170267768A1 (es) |
EP (1) | EP3429624A4 (es) |
JP (1) | JP2019515645A (es) |
KR (1) | KR20180127344A (es) |
CN (1) | CN108778328A (es) |
AU (1) | AU2017234275A1 (es) |
BR (1) | BR112018015898A2 (es) |
CA (1) | CA3016676A1 (es) |
MX (1) | MX2018009389A (es) |
SG (1) | SG11201807336RA (es) |
TW (1) | TW201738275A (es) |
WO (1) | WO2017160775A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2595657A4 (en) * | 2010-07-22 | 2015-09-23 | Univ California | ANTITUMOR ANTIBODY ANTIBODIES AND METHODS OF USING SAME |
CN109467593A (zh) * | 2018-11-30 | 2019-03-15 | 北京泽勤生物医药有限公司 | 低pH插入肽的胞外段作为抗原的应用 |
CN114437205A (zh) * | 2020-11-05 | 2022-05-06 | 多玛医药科技(苏州)有限公司 | 抗冠状病毒抗体及其应用 |
CN117693519A (zh) | 2021-05-25 | 2024-03-12 | 瓦克斯细胞生物 | 基于单体拟抗体的嵌合抗原受体和包含其的免疫细胞 |
CN113651889B (zh) * | 2021-07-16 | 2023-06-02 | 西南医科大学 | 一种抗EphA2全人源双价重组抗体scFv-Fc |
CN118055945A (zh) * | 2021-08-06 | 2024-05-17 | 韩国生命工学研究院 | 新型抗epha2嵌合抗原受体和表达其的免疫细胞 |
CN113980138B (zh) * | 2021-08-11 | 2023-08-11 | 卡瑞济(北京)生命科技有限公司 | EphA2嵌合抗原受体以及其用途 |
WO2023196869A1 (en) * | 2022-04-05 | 2023-10-12 | Atreca, Inc. | Epha2 antibodies |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040260068A1 (en) * | 2004-02-26 | 2004-12-23 | Naoya Tsurushita | Humanized chicken antibodies |
DK2352763T4 (da) * | 2008-10-01 | 2022-10-17 | Amgen Res Munich Gmbh | Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener |
CA2790289A1 (en) * | 2010-02-18 | 2011-08-25 | Meiji Seika Pharma Co., Ltd. | Antibody against serotype b lipopolysaccharide of pseudomonas aeruginosa |
EP2595657A4 (en) * | 2010-07-22 | 2015-09-23 | Univ California | ANTITUMOR ANTIBODY ANTIBODIES AND METHODS OF USING SAME |
JP2014505698A (ja) * | 2011-02-02 | 2014-03-06 | グラクソ グループ リミテッド | 新規抗原結合タンパク質 |
EP2736925A2 (en) * | 2011-07-27 | 2014-06-04 | Glaxo Group Limited | Anti-vegf single variable domains fused to fc domains |
EP2716298A1 (en) * | 2012-10-03 | 2014-04-09 | Institut Pasteur | A nod2-dependant pathway of cytoprotection of stem cells |
SG11201807148RA (en) * | 2016-03-16 | 2018-09-27 | Merrimack Pharmaceuticals Inc | Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions |
-
2017
- 2017-03-13 AU AU2017234275A patent/AU2017234275A1/en not_active Abandoned
- 2017-03-13 KR KR1020187026565A patent/KR20180127344A/ko unknown
- 2017-03-13 CA CA3016676A patent/CA3016676A1/en not_active Abandoned
- 2017-03-13 CN CN201780009432.0A patent/CN108778328A/zh active Pending
- 2017-03-13 EP EP17767295.3A patent/EP3429624A4/en not_active Withdrawn
- 2017-03-13 JP JP2018541670A patent/JP2019515645A/ja active Pending
- 2017-03-13 US US15/457,857 patent/US20170267768A1/en not_active Abandoned
- 2017-03-13 SG SG11201807336RA patent/SG11201807336RA/en unknown
- 2017-03-13 BR BR112018015898A patent/BR112018015898A2/pt not_active Application Discontinuation
- 2017-03-13 WO PCT/US2017/022188 patent/WO2017160775A1/en active Application Filing
- 2017-03-13 MX MX2018009389A patent/MX2018009389A/es unknown
- 2017-03-15 TW TW106108588A patent/TW201738275A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP3429624A1 (en) | 2019-01-23 |
TW201738275A (zh) | 2017-11-01 |
CN108778328A (zh) | 2018-11-09 |
JP2019515645A (ja) | 2019-06-13 |
BR112018015898A2 (pt) | 2019-01-22 |
EP3429624A4 (en) | 2020-04-22 |
MX2018009389A (es) | 2018-11-21 |
CA3016676A1 (en) | 2017-09-21 |
US20170267768A1 (en) | 2017-09-21 |
AU2017234275A1 (en) | 2018-10-04 |
WO2017160775A1 (en) | 2017-09-21 |
KR20180127344A (ko) | 2018-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807336RA (en) | Protein a binding polypeptides, anti-epha2 antibodies and methods of use thereof | |
SG11201807176XA (en) | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201909499QA (en) | Humanized antigen-binding domains against cd19 and methods of use | |
SG11201810509PA (en) | Anti-pd-l1 antibodies | |
SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201805449PA (en) | Methods of making chimeric antigen receptor -expressing cells | |
SG11201808979UA (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof | |
SG11201901528RA (en) | Proteolytically cleavable chimeric polypeptides and methods of use thereof | |
SG11201810883TA (en) | Combination therapy | |
SG11201807437XA (en) | Antibodies specific to human poliovirus receptor (pvr) | |
SG11201810640RA (en) | Cd33 specific chimeric antigen receptors | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
SG11201807401RA (en) | Therapeutic membrane vesicles | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201808693WA (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof |